67-4

68/90

388interneurons derived from induced pluripo-tent stem cells of patients with parkin muta-tions. Mol Brain, 2019 Jan 18; 12: 5. doi: 10.1186/ s13041-019-0426-7. PubMed PMID: 30658665; PubMed Central PMCID: PMC6339354. 29) Kamagata K, Zalesky A, Yokoyama K, Andica C, Hagiwara A, Shimoji K, Kumamaru KK, Takemura MY, Hoshino Y, Kamiya K, Hori M, Pantelis C, Hattori N, Aoki S: MR g-ra-tio-weighted connectome analysis in patients with multiple sclerosis. Sci Rep, 2019 Sep 18; 9: 13522. doi: 10.1038/s41598-019-50025-2. 30) Kamo H, Hatano T, Kanai K, Aoki N, Kami-yama D, Yokoyama K, Takanashi M, Yamashita Y, Shimo Y, Hattori N: Pembrolizumab-re-lated systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol, 2019 Aug 5; 19: 184. doi: 10.1186/s12883-019-1416-1. 31) Kawamura M, Sato S, Matsumoto G, Fukuda T, Shiba-Fukushima K, Noda S, Takanashi M, Mori N, Hattori N: Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkin-son’s disease patients. Neurosci Lett, 2019 Apr 23; 699: 59-63. doi: 10.1016/j.neulet.2019. 01.042. 32) Le Berre A, Kamagata K, Otsuka Y, Andica C, Hatano T, Saccenti L, Ogawa T, Takeshige-Amano H, Wada A, Suzuki M, Hagiwara A, Irie R, Hori M, Oyama G, Shimo Y, Umemura A, Hattori N, Aoki S: Convolutional neural network-based segmentation can help in assessing the substantia nigra in neuromel-anin MRI. Neuroradiology, 2019; 61: 1387-1395. doi: 10.1007/s00234-019-02279-w. 33) Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu Y, Kim DK, Jung BC, Choi M, Oh KW, Li Y, Nakatani M, Nakazato T, Sekimoto S, Funayama M, Yoshino H, Kubo SI, Nishioka K, Sakai R, Ueyama M, Mochizuki H, Lee HJ, Sardi SP, Halliday GM, Nagai Y, Lee PH, Hattori N, Lee SJ: Arylsulfatase A, a genetic modifier of Parkinson’s disease, is an α-synu-clein chaperone. Brain, 2019 Sep 1; 142: 2845-2859. doi:10.1093/brain/awz205. 34) Magami S, Miyamoto N, Ueno Y, Hira K, Tanaka R, Yamashiro K, Oishi H, Arai H, Urabe T, Hattori N: The Effects of Astrocyte and Oligodendrocyte Lineage Cell Interac-tion on White Matter Injury under Chronic Cerebral Hypoperfusion. Neuroscience. 2019 May 15; 406: 167-175. doi: 10.1016/j.neurosci-ence.2019.03.004. 35) Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Inves-tigators and the PATH Study Group (incl. Yokoyama K): Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies, J Peripher Nerv Syst, 2019 Mar; 24: 48-55. 36) Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group (incl. Yokoyama K): Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflam-matory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. J Peripher Nerv Syst, 2019 Mar; 24: 72-79. 37) Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N: Long-Term Selegiline Mono-therapy for the Treatment of Early Parkinson Disease. Clin Neuropharmacol, 2019 Apr 30; 42: 123-130. doi: 10.1097/WNF.0000000000000343.＊ 38) Mori A, Hatano T, Inoshita T, Shiba-Fukushima K, Koinuma T, Meng H, Kubo SI, Spratt S, Cui C, Yamashita C, Miki Y, Yamamoto K, Hirabayashi T, Murakami M, Takahashi Y, Shindou H, Nonaka T, Hasegawa M, Okuzumi A, Imai Y, Hattori N: Parkinson’s disease-as-sociated regulates neuronal functions and α-synuclein stability through membrane remodeling. Proc Natl Acad Sci U S A, 2019 Oct 8; 116: 20689-20699. doi: 10.1073/pnas.1902958116. 39) Mori A, Ishikawa KI (co-first author), Saiki S, Hatano T, Oji Y, Okuzumi A, Fujimaki M, Koinuma T, Ueno SI, Imamichi Y, Hattori N: Plasma metabolite biomarkers for multiple system atrophy and progressive supranu-clear palsy, 27; 14: e0223113. doi: 10.1371/iPLA2-VIA/PLA2G6